Back
HCV Disease Progression 
Decompensation & ESLD
Decompensation & ESLD
EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival
- Details
- Category: Decompensation & ESLD
- Published on Wednesday, 03 May 2017 00:00
- Written by Liz Highleyman
Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.
More Articles...
- EASL 2017: Hepatitis C Treatment Allows 1 in 4 to Come Off Liver Transplant Waiting List
- EASL 2016: Hepatitis C Treatment May Not Stop Progression to Advanced Liver Disease
- DDW 2015: Cirrhosis and Decompensation Are Common Among People with Chronic Hepatitis C
- EASL 2015: Hepatitis C Treatment Effective for People with Advanced Liver Disease
- 10. Hepatitis C Cures for HIV/HCV Coinfected and Advanced Liver Disease
- AASLD 2014: Many Hepatitis C Patients with Cirrhosis or Advanced Fibrosis Face Liver Failure
- AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use
- AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
- AASLD 2014: Daclatasvir + Sofosbuvir Demonstrates Good Cure Rate for HCV Genotype 3 Patients
- AASLD 2014: Sofosbuvir + GS-5816 for 12 Weeks Shows High Cure Rates, 8 Weeks Less Effective
- AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
- AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Highly Effective for People with Decompensated Cirrhosis
- AASLD 2014: Sofosbuvir/Ledipasvir and AbbVie 2D Cure Most People with HCV Genotype 4
- Hepatitis C Liver Decompensation Remains a Problem for People with HIV Despite Good ART
- IAS 2013: FibroScan Predicts Liver Decompensation and Death Among HIV/HCV Coinfected People
- HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C
- Rifaximin Reduces Encephalopathy Recurrence, Improves Quality of Life in People with Liver Cirrhosis
- Antibiotic Rifaximin Maintains Remission of Hepatic Encephalopathy in People with Advanced Liver Disease
Web Design and Development by